Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial-Reference-Cited by-同舟云学术

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

Published:2017-08 Issue:8 Volume:16 Page:591-600
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Chan Dennis,Binks Sophie,Nicholas Jennifer M,Frost Chris,Cardoso M Jorge,Ourselin Sebastien,Wilkie David,Nicholas Richard,Chataway Jeremy

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference32 articles.

1. Cognitive impairment in multiple sclerosis;Chiaravalloti;Lancet Neurol,2008

2. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis;Planche;Eur J Neurol,2016

3. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning;Rao;Neurology,1991

4. Treatment of cognitive impairment in multiple sclerosis: position paper;Amato;J Neurol,2013

5. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis;Rocca;Lancet Neurol,2015

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disability independent of cerebral white matter demyelination in progressive multiple sclerosis;Acta Neuropathologica;2024-08-31

2. Survey on diagnosis of post-brain injury “higher brain dysfunction” in patients with cognitive impairment. Family/caregiver response;Applied Neuropsychology: Adult;2024-07-06

3. Efficacy and acceptability of anti-inflammatory agents in major depressive disorder: a systematic review and meta-analysis;Frontiers in Psychiatry;2024-05-28

4. Cool the Inflamed Brain: A Novel Anti-inflammatory Strategy for the Treatment of Major Depressive Disorder;Current Neuropharmacology;2024-05

5. New target-HMGCR inhibitors for the treatment of primary sclerosing cholangitis: a drug Mendelian randomization study;2024-04-25